ellipticine-1-carboxamide | 85619-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ellipticine-1-carboxamide
• 英文别名: 5,11-Dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide
• CAS: 85619-27-8
• 化学式: C₁₈H₁₅N₃O
• 分子量: 289.337
• InChiKey: LXKIIMAUMJSHGL-UHFFFAOYSA-N

物化性质

• 沸点：
  639.6±50.0 °C(Predicted)
• 密度：
  1.348±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  71.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  椭圆玫瑰树碱 在 氢氧化钾 、 水 、 sodium hydride 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 ellipticine-1-carboxamide
  参考文献：
  名称：

  潜在抗肿瘤药的合成。二十七。（Reissert化合物研究。XLIV。）。玫瑰树碱Reissert化合物作为玫瑰树碱类似物的合成中间体

  摘要：

  玫瑰树碱和许多玫瑰树碱类似物被转化为Reissert化合物。6-苄基玫瑰树碱Reissert化合物的烷基化反应产生了一系列1-取代的6-苄基玫瑰树碱。通过Reissert化合物获得的1-氰基玫瑰树碱被水解为玫瑰树碱1-羧酰胺盐酸盐，该盐对P388淋巴细胞性白血病具有活性。玫瑰树碱Reissert化合物的化学反应的其他方面也有所介绍。

  DOI：

  10.1002/jhet.5570190603

文献信息

• [EN] BONE MORPHOGENETIC PROTEIN PATHWAY ACTIVATION, COMPOSITIONS FOR OSSIFICATION, AND METHODS RELATED THERETO<br/>[FR] ACTIVATION DE LA VOIE DES PROTÉINES MORPHOGÉNÉTIQUES OSSEUSES, COMPOSITIONS POUR UNE OSSIFICATION ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2014011540A1

  公开（公告）日：2014-01-16

  The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as 2-(2-Methoxybenzylidene)-1-indanone; N-(4-arsonophenyl)glycine; 1,2-Benzenedicarboxylic acid, 1-(1-methylheptyl) ester; (4'-hydroxybiphenyl-4-yl)(phenyl)methanone; 2,2-dimethylchroman-6-carboxylic acid, (4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)amide; Ethyl 2-((4-chlorophenyl)thio)-1,3-benzothiazol-6-yl carbamate; Ethyl (2-(azepan-1-yl)benzo[d]thiazol-6-yl) carbamate; Porfiromycin;1,3-benzodioxol-5-yl-[4-(3,4,5-trimethoxybenzoyl)-3-furyl]methanone; Tricinolone acetophenonide; 2,4-bis(3,4-dimethoxyphenyl)-4H-pyrano[3,2-c]chromen-5-one; Methyl 5-fluoro-4-methoxy-2,6-dioxohexahydro-5-pyrimidine carboxylate; 5-(naphthalen-1-yl)-1-phenyl-1h-tetrazole; 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ol; N-[2,4,5-trimethyl-4-(trichloromethyl)cyclohexa-2,5-dien-1-ylidene]hydroxylamine; 4-benzoyl-3,4-dihydro-Benzo[f]quinoline-3-carbonitrile; 2-nitro-3-phenylspiro[cyclopropane-1,9'-fluorene]; 3-[4-(furan-2-ylmethyl)-5-sulfanylidene-1,2,4-dithiazolidin-3-ylidene]-1,1-dimethylthiourea; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl) 2-methoxyacetate; 5-Iodo-1H-indole-2,3-dione; 4,5-dihydro-1,2,9,10-tetramethoxy dibenzo[de,g]quinoline-6-carboxylic acid, ethyl ester; [2,6-bis(2,4-dimethylphenyl)-4-(2-methoxyacetyl)oxy-phenyl] 2-methoxyacetate; 5,11-dimethyl-2-(2-piperidin-1-ylethyl)-6H-pyrido[4,3-b]carbazol-2-ium-9-ol; 2-[3-[[4-[(3-nitroacridin-9-yl)amino]phenyl]sulfamoyl] propyl]guanidine; 1-[[2-(dimethylamino)ethyl]amino]-7-hydroxy-4-methyl-9H-thioxanthen-9-one; 5-amino-1H-1,2,4-triazole-3-carboxylic acid, methyl ester; methyl N-cyano-N'-prop-2-en-1-ylcarbamimidothioate; 5,7-dinitro-8-quinolinol; 5-nitrosoquinolin-8-ol; Cantharidin; 1,7-Diaminoacridine; 3-Methyl-3-(1-naphthyl)-2-benzofuran-1(3H)-one; Dichlorolapachol; Lycobetaine; 6-(1-aziridinyl)- 2,3-dihydro-3-(propionyl)-7-methyl-1H-Pyrrolo [1,8]-dione; 4-Nitroestrone 3-methyl ether; 5,11-dimethyl-6H-pyrido[4,3-b] carbazole-1-carboxamide hydrochloride; 5-Methoxysterigmatocysin; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1H-pyrrolo[1,2-a]benzimidazol-3-yl) 2-methoxyacetate; Horminon; 7',8'-dimethyl-2'-oxo-4',4a',6a',7'- tetrahydro-2'H-spiro[oxirane-2,1'-pentaleno[1,6a-c]pyran]-5'-carboxylate; Nybomycin acetate; 5H-[1,6]indeno[1,2-c]isoquinoline-5,12-dione; 2,3-dimethoxy-6-methyl-Nitidine; Iproplatin; 3-[(deoxyhexosyl)oxy]-2-(3,4-dihydroxyphenyl)-6,8-dihdroxy-4H-1-Benzopyran-4-one; 2-O-benzyl 8-O-methyl 3-(4-methylphenyl)sulfonyl-4,5-dioxo-6H- pyrrolo[3,2-e]indole-2,8- dicarboxylate;6-bromo-5,8-dihydroxy-7-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl] naphthalene -1,4-dione; 5-methylbenzo[c]phenanthridin-5-ium-2,3,8,9-tetrol; (6-acetyl-4-oxo-1,3-diphenyl-2-sulfanylidenethieno[2,3-d]pyrimidin-5-yl)-2,4-dichlorobenzoate; N-[C-[4-[bis(2-cyanoethyl)amino]-2-methylphenyl]-N-(4-methylanilino)carbonimidoyl]imino-4-methylbenzamide; Gelcohol; Curcumin; Tirandamycin; Noscapine; Aristolochic acid; Himbacine; Fumagillin; Fumitremorgin C; Physalin B; derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement. In certain embodiments, compounds disclosed herein are useful for managing obesity and diabetes or other metabolic syndromes by modulation of brown fat.
• Synthesis of potential antineoplastic agents. XXVII. (Reissert compound studies. XLIV.). The ellipticine reissert compound as an intermediate in the syntheses of ellipticine analogs
  作者：Frank D. Popp、Seshadri Veeraraghavan

  DOI：10.1002/jhet.5570190603

  日期：1982.11

  were converted to Reissert compounds. Alkylation of the 6-benzylellipticine Reissert compound gave a series of 1-substituted-6-benzylellipticines. 1-Cyanoellipticine, obtained through the Reissert compound, was hydrolyzed to ellipticine-1-carboxamide hydrochloride which was active against P388 lymphocytic leukemia. Other aspects of the chemistry of the ellipticine Reissert compound are presented.

  玫瑰树碱和许多玫瑰树碱类似物被转化为Reissert化合物。6-苄基玫瑰树碱Reissert化合物的烷基化反应产生了一系列1-取代的6-苄基玫瑰树碱。通过Reissert化合物获得的1-氰基玫瑰树碱被水解为玫瑰树碱1-羧酰胺盐酸盐，该盐对P388淋巴细胞性白血病具有活性。玫瑰树碱Reissert化合物的化学反应的其他方面也有所介绍。